Abigail M. Wojtowicz, PhD

Takeda

Poster(s):

• P0917 - Low Rates of Transition From Subcutaneous to Intravenous Formulation in Patients With Inflammatory Bowel Diseases Treated With Vedolizumab
  Sunday, October 27, 2024

  3:30 PM – 7:00 PM ET

• P0918 - Comparative Efficacy and Safety of Subcutaneous Vedolizumab versus Other Targeted Inflammatory Bowel Disease Therapies in Patients With Moderate to Severe Ulcerative Colitis: A Network Meta-Analysis
  Sunday, October 27, 2024

  3:30 PM – 7:00 PM ET